Roche's Partnership Playbook: A Closer Look At 2023's Successes And 2024's Prospects
After chasing late-stage assets in 2023, Roche is moving back to its more diverse dealmaking approach. The company’s global head of pharma partnering, James Sabry, spoke to In Vivo about the value of partnerships at Roche and the formula for a successful collaboration.
You may also be interested in...
Scrip spoke with Roche Pharmaceuticals CEO Teresa Graham about efforts to boost product sales, build out the drug development portfolio and return the company to revenue growth.
The Swiss pharma sees the acquisition as the ‘backbone’ for its future cardiometabolic portfolio, which could include a combination with a muscle-building therapy.
As Bayer moves through a challenging period, business development, licensing and impact investment may help buttress the company’s resilience.